News
ANVS
5.18
-4.95%
-0.27
Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market
Annovis Bio's pipeline features a single therapeutic drug, buntanetap, unlikely to showcase efficacy in Alzheimer's disease or Parkinson's disease. Topline data of AD phase II/III trial was released in a press release, and featured a small post-hoc sub-population. The stock plummeted 70% on press release announcements. Annovis has delayed its PD trial results and is running low on funds.
Seeking Alpha · 3d ago
Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects
Annovis Bio, Inc. Is a clinical-stage pharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and Parkinson's. Its pipeline includes Buntanetap/ANVS 402 for AD, PD, and Lewy Body Dementia, as well as other promising drugs for traumatic brain injuries and stroke. Annovis is preparing for Phase 3 trials in Alzheimer's. The recent drop in ANVS stock following mixed clinical trial results present potential risks. I rate ANVS Bio a 'hold' due to promising yet mixed clinical results and potential upcoming catalysts.
Seeking Alpha · 3d ago
Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales
NASDAQ · 3d ago
Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap Into Question
Annovis Bio, Inc. Reported topline data from a Phase 2/3 trial in Alzheimer's disease, but the trial was a failure. The exclusion of 37% of the patient population and focus on mild AD patients were not pre-specified, raising concerns. I have covered Annovis before with a Hold rating in October 2023. The company faces financial challenges and may see a significant decline in stock prices.
Seeking Alpha · 4d ago
Annovis Bio CFO Henry Hagopian Resigns, CEO Steps In
TipRanks · 4d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Akili stock moved upwards by 70.1% to $0.4 during Tuesday's regular session. Cyclacel Pharmaceuticals (NASDAQ:CYCC) stock rose 51.83%. Eliem Therapeutics shares rose 50.0% during the regular session to $7.53.
Benzinga · 5d ago
Annovis Bio, Cyclacel Pharmaceuticals, Biodexa Pharmaceuticals among healthcare movers
Seeking Alpha · 5d ago
NIVF, BDRX and ZAPP among pre-market losers
Seeking Alpha · 5d ago
Annovis Bio Is Maintained at Buy by Canaccord Genuity
Dow Jones · 5d ago
Annovis Bio Price Target Cut to $26.00/Share From $36.00 by Canaccord Genuity
Dow Jones · 5d ago
Canaccord Genuity Maintains Buy on Annovis Bio, Lowers Price Target to $26
Benzinga · 5d ago
Annovis Bio Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Dow Jones · 5d ago
Analysts Conflicted on These Healthcare Names: Annovis Bio (ANVS), Gilead Sciences (GILD) and Omega Therapeutics (OMGA)
TipRanks · 5d ago
HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target
Benzinga · 5d ago
Annovis Bio: Searching For Efficacy In Alzheimer's Disease
Seeking Alpha · 5d ago
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
U.S. Stocks traded higher toward the end of trading on Monday. The Dow traded up 0.19% and the Nasdaq Composite gained around 0.1%. ON Semiconductor Corp. Reported better-than-expected first-quarter results. Asian markets closed higher and European markets were mixed. Consumer discretionary shares rose by 1.9% on Monday; communication services shares fell 1.7%.
Benzinga · 6d ago
Why Is Alzheimer's-Focused Annovis Bio Stock Nosediving On Monday?
Annovis Bio Inc (NASDAQ:ANVS) shares plunged after the company released data from its Phase 2/3 Alzheimer study of buntanetap in mild to moderate Alzheimer’s patients. The 15mg and 30mg groups slightly improved in mild Alzheimer's patients. All three treatment groups showed statistically significant improvement.
Benzinga · 6d ago
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Clever Leaves Holdings Inc. Shares dipped 60% to $1.6498 on Monday. The company announced it will voluntarily delist its common shares from the Nasdaq. Shares of Deciphera Pharmaceuticals, Inc. Climbed 73% in today's mid-day session.
Benzinga · 6d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The company's Q1 earnings report came out today. Deciphera shares rose to $2.0 billion. SINTX Techs and Koninklijke Philips also moved upwards.
Benzinga · 6d ago
Annovis Bio Shares Sink After Buntanetap Study Misses Endpoint
Annovis Bio's stock was down 59% at $7.32 on heavy volume. The company's drug candidate for Alzheimer's disease missed a primary endpoint in a phase 2/3 study. The drug candidate buntanetap is being tested as a treatment for the disease. Annovis says it plans to conduct a phase 3 study.
Dow Jones · 6d ago
More
Webull provides a variety of real-time ANVS stock news. You can receive the latest news about Annovis Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANVS
Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic neurodegenerative diseases. The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from six to three.